1986: Preliminary study of IFN for NANB hepatitisHoofnagle, et al. NEJM; 315: 1575-8

• 10 pts with chronic NANB hepatitis.

• Variable dosing with IFN alfa-2b for variable length of therapy.

• 8/10 pts had mean ALT decrease of 206 u/L, mean AST decrease of 76 u/L.

• 3 patients had repeat biopsies showing histologic improvement.

• No post-treatment follow up.

• Concluded that IFN caused prompt improvement in aminotransferase levels and histology; RCTs needed.

• Study supported by Schering Corporation.

Previous slide

Next slide

Back to first slide

View graphic version